New Tyrosine Kinase Inhibitor
Author Information
Author(s): Ma Jingui, Xin Xianliang, Meng Linghua, Tong Linjiang, Lin Liping, Geng Meiyu, Ding Jian
Primary Institution: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Hypothesis
The aim of the present study was to identify novel multi-targeting PTK inhibitors.
Conclusion
MdOS, a novel marine-derived oligosaccharide sulfate, exhibited anti-angiogenic activity in a PTK-dependent manner and is a promising agent for cancer therapy.
Supporting Evidence
- MdOS inhibited the kinase activities of HER-2, EGFR, and VEGFR2 with IC50 values of 0.13, 0.28, and 1.8 µg/ml, respectively.
- MdOS blocked tyrosine kinase phosphorylation and downstream signaling in various cancer cell lines.
- In vivo studies showed that MdOS significantly inhibited neovascularization in a chicken chorioallantoic membrane model.
Takeaway
MdOS is a new type of medicine made from sea ingredients that helps stop cancer by blocking certain proteins that help tumors grow.
Methodology
The study used enzyme-linked immunosorbent assay (ELISA), sulforhodamine (SRB) assay, western blot analysis, and various in vitro and in vivo assays to evaluate the effects of MdOS.
Potential Biases
Potential bias may arise from the use of specific cell lines and animal models that may not fully represent human cancer biology.
Limitations
The study does not address the long-term effects of MdOS or its efficacy in human subjects.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website